Download FREE Report Sample
Download Free sampleRituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
Biosimilars of Rituximab Market contains market size and forecasts of Biosimilars of Rituximab in global, including the following market information:
Global Biosimilars of Rituximab Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Biosimilars of Rituximab Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Biosimilars of Rituximab companies in 2021 (%)
The global Biosimilars of Rituximab market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
500mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biosimilars of Rituximab include Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy?s Laboratories, Teva, Hetero Group and Innovent Biologics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
surveyed the Biosimilars of Rituximab manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilars of Rituximab Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilars of Rituximab Market Segment Percentages, by Type, 2021 (%)
500mg
100mg
Other
Global Biosimilars of Rituximab Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilars of Rituximab Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Global Biosimilars of Rituximab Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilars of Rituximab Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilars of Rituximab revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Biosimilars of Rituximab revenues share in global market, 2021 (%)
Key companies Biosimilars of Rituximab sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Biosimilars of Rituximab sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy?s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
